PMID- 38432342
OWN - NLM
STAT- MEDLINE
DCOM- 20240419
LR  - 20240419
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
VI  - 218
DP  - 2024 May 1
TI  - Safety and Efficacy of Enoxaparin During Low-Risk Elective Percutaneous Coronary 
      Intervention.
PG  - 63-67
LID - S0002-9149(24)00157-7 [pii]
LID - 10.1016/j.amjcard.2024.02.033 [doi]
AB  - Intravenous unfractionated heparin (UFH) is the most frequently used 
      anticoagulant for percutaneous coronary intervention (PCI). Intravenous 
      enoxaparin, a low-molecular-weight heparin, has superior pharmacokinetic and 
      pharmacodynamic properties compared with UFH. Multiple trials have shown 
      enoxaparin to be safe and effective in PCI. However, there has not been a 
      contemporary study evaluating its safety and efficacy. To assess its efficacy and 
      safety, intravenous enoxaparin during PCI through radial artery access was 
      evaluated in PCI patients from January 2015 to December 2019. Outcomes included 
      procedural success, all-cause mortality, ischemic complications, and bleeding 
      complications from the time of the procedure until hospital discharge. A total of 
      1019 consecutive eligible patients were identified. Median age was 63 years, and 
      70% were men. The indication for PCI was stable and unstable angina in two-thirds 
      of cases (77%). Few patients had myocardial infarction (MI) (2.2%) as the 
      indication for intervention. The procedure was successful in 98.2% of cases. 
      There were no deaths. Procedural MI occurred in 0.3% of patients. Acute stent 
      thrombosis occurred in 0.4%. Urgent revascularization and stroke occurred in 0.1% 
      each. Small wrist hematomas occurred in 0.3% and all were managed conservatively. 
      There was one radial artery pseudoaneurysm. There were no cases of major 
      bleeding. In conclusion, this single-center study showed that intravenous 
      enoxaparin is a reasonable alternative anticoagulant for use in low-risk and 
      elective non-MI PCI through radial artery access.
CI  - Copyright (c) 2024 Elsevier Inc. All rights reserved.
FAU - Alturkmani, Hani
AU  - Alturkmani H
AD  - Department of Cardiovascular Medicine, University of Arkansas for Medical 
      Sciences, Little Rock, Arkansas. Electronic address: hani.alturkmani@gmail.com.
FAU - Uretsky, Barry
AU  - Uretsky B
AD  - Department of Cardiovascular Medicine, University of Arkansas for Medical 
      Sciences, Little Rock, Arkansas; Department of Cardiology, Central Arkansas 
      Veterans Affairs Healthcare System, Little Rock, Arkansas.
FAU - Patel, Swetal
AU  - Patel S
AD  - Department of Cardiology, University of Nevada Las Vegas, Las Vegas, Nevada.
FAU - Albadaineh, Mu'nes
AU  - Albadaineh M
AD  - Department of Internal Medicine, University of Arkansas for Medical Sciences, 
      Little Rock, Arkansas.
FAU - Alqaisi, Omar
AU  - Alqaisi O
AD  - Department of Internal Medicine, University of Arkansas for Medical Sciences, 
      Little Rock, Arkansas.
FAU - Alaiwah, Malek
AU  - Alaiwah M
AD  - Department of Cardiovascular Medicine, University of Arkansas for Medical 
      Sciences, Little Rock, Arkansas.
FAU - Cross, Michael
AU  - Cross M
AD  - Department of Cardiovascular Medicine, University of Arkansas for Medical 
      Sciences, Little Rock, Arkansas.
FAU - Abbasi, Danish
AU  - Abbasi D
AD  - Department of Cardiovascular Medicine, University of Arkansas for Medical 
      Sciences, Little Rock, Arkansas.
FAU - Rollefson, William
AU  - Rollefson W
AD  - Department of Cardiology, Arkansas Heart Hospital, Little Rock, Arkansas.
LA  - eng
PT  - Journal Article
DEP - 20240301
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Enoxaparin)
RN  - 9005-49-6 (Heparin)
RN  - 0 (Anticoagulants)
SB  - IM
MH  - Male
MH  - Humans
MH  - Middle Aged
MH  - Female
MH  - Enoxaparin
MH  - Heparin
MH  - *Percutaneous Coronary Intervention
MH  - Treatment Outcome
MH  - Anticoagulants
MH  - *Myocardial Infarction
OTO - NOTNLM
OT  - anticoagulation
OT  - enoxaparin
OT  - heparin
OT  - percutaneous coronary intervention
COIS- Declaration of competing interest The authors have no competing interests to 
      declare.
EDAT- 2024/03/04 00:43
MHDA- 2024/04/19 06:43
CRDT- 2024/03/03 19:14
PHST- 2023/08/21 00:00 [received]
PHST- 2024/02/01 00:00 [revised]
PHST- 2024/02/23 00:00 [accepted]
PHST- 2024/04/19 06:43 [medline]
PHST- 2024/03/04 00:43 [pubmed]
PHST- 2024/03/03 19:14 [entrez]
AID - S0002-9149(24)00157-7 [pii]
AID - 10.1016/j.amjcard.2024.02.033 [doi]
PST - ppublish
SO  - Am J Cardiol. 2024 May 1;218:63-67. doi: 10.1016/j.amjcard.2024.02.033. Epub 2024 
      Mar 1.